Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

W Mahaffey

Showing results (321-330 of 627) with videos related to

Pageof 63
Sort By:
Journal of the American College of Cardiology|January 14, 2017
Cangrelor With and Without Glycoprotein IIb/IIIa Inhibitors in Patients Undergoing Percutaneous Coronary InterventionMuthiah Vaduganathan, Robert A Harrington, Gregg W Stone, et al.
Journal of the American College of Cardiology|October 2, 2012
Factors contributing to the lower mortality with ticagrelor compared with clopidogrel in patients undergoing coronary artery bypass surgeryChristoph Varenhorst, Ulrica Alström, Benjamin M Scirica, et al.
Eurointervention : Journal of Europcr in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology|October 9, 2017
Short- and long-term mortality following bleeding events in patients undergoing percutaneous coronary intervention: insights from four validated bleeding scales in the CHAMPION trialsMuthiah Vaduganathan, Robert A Harrington, Gregg W Stone, et al.
Heart (British Cardiac Society)|March 4, 2015
Heart rate is associated with progression of atrial fibrillation, independent of rhythmFredrik Holmqvist, Sunghee Kim, Benjamin A Steinberg, et al.
European Heart Journal. Quality of Care & Clinical Outcomes|August 26, 2017
Management and outcomes of patients with atrial fibrillation and a history of cancer: the ORBIT-AF registryChiara Melloni, Peter Shrader, Joseph Carver, et al.
The American Journal of Cardiology|November 11, 2015
Racial Differences in Quality of Anticoagulation Therapy for Atrial Fibrillation (from the TREAT-AF Study)Celina Yong, Farnaz Azarbal, Freddy Abnousi, et al.
Circulation|July 1, 2016
On-Treatment Outcomes in Patients With Worsening Renal Function With Rivaroxaban Compared With Warfarin: Insights From ROCKET AFChristopher B Fordyce, Anne S Hellkamp, Yuliya Lokhnygina, et al.
Circulation. Cardiovascular Interventions|April 11, 2018
Incidence, Predictors, and Outcomes of Acquired Thrombocytopenia After Percutaneous Coronary Intervention: A Pooled, Patient-Level Analysis of the CHAMPION Trials (Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition)Elliott M Groves, Deepak L Bhatt, Philippe Gabriel Steg, et al.
Circulation|January 26, 1999
Effects of stroke on medical resource use and costs in acute myocardial infarction. GUSTO I Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries StudyC Y Tung, C B Granger, M A Sloan, et al.
JAMA|November 24, 2005
High-risk patients with acute coronary syndromes treated with low-molecular-weight or unfractionated heparin: outcomes at 6 months and 1 year in the SYNERGY trialKenneth W Mahaffey, Marc Cohen, Jyotsna Garg, et al.
Pageof 63

Showing results (321-330 of 627) with videos related to

Sort By:
Pageof 63
Journal of the American College of Cardiology|January 14, 2017
Cangrelor With and Without Glycoprotein IIb/IIIa Inhibitors in Patients Undergoing Percutaneous Coronary InterventionMuthiah Vaduganathan, Robert A Harrington, Gregg W Stone, et al.
Journal of the American College of Cardiology|October 2, 2012
Factors contributing to the lower mortality with ticagrelor compared with clopidogrel in patients undergoing coronary artery bypass surgeryChristoph Varenhorst, Ulrica Alström, Benjamin M Scirica, et al.
Eurointervention : Journal of Europcr in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology|October 9, 2017
Short- and long-term mortality following bleeding events in patients undergoing percutaneous coronary intervention: insights from four validated bleeding scales in the CHAMPION trialsMuthiah Vaduganathan, Robert A Harrington, Gregg W Stone, et al.
Heart (British Cardiac Society)|March 4, 2015
Heart rate is associated with progression of atrial fibrillation, independent of rhythmFredrik Holmqvist, Sunghee Kim, Benjamin A Steinberg, et al.
European Heart Journal. Quality of Care & Clinical Outcomes|August 26, 2017
Management and outcomes of patients with atrial fibrillation and a history of cancer: the ORBIT-AF registryChiara Melloni, Peter Shrader, Joseph Carver, et al.
The American Journal of Cardiology|November 11, 2015
Racial Differences in Quality of Anticoagulation Therapy for Atrial Fibrillation (from the TREAT-AF Study)Celina Yong, Farnaz Azarbal, Freddy Abnousi, et al.
Circulation|July 1, 2016
On-Treatment Outcomes in Patients With Worsening Renal Function With Rivaroxaban Compared With Warfarin: Insights From ROCKET AFChristopher B Fordyce, Anne S Hellkamp, Yuliya Lokhnygina, et al.
Circulation. Cardiovascular Interventions|April 11, 2018
Incidence, Predictors, and Outcomes of Acquired Thrombocytopenia After Percutaneous Coronary Intervention: A Pooled, Patient-Level Analysis of the CHAMPION Trials (Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition)Elliott M Groves, Deepak L Bhatt, Philippe Gabriel Steg, et al.
Circulation|January 26, 1999
Effects of stroke on medical resource use and costs in acute myocardial infarction. GUSTO I Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries StudyC Y Tung, C B Granger, M A Sloan, et al.
JAMA|November 24, 2005
High-risk patients with acute coronary syndromes treated with low-molecular-weight or unfractionated heparin: outcomes at 6 months and 1 year in the SYNERGY trialKenneth W Mahaffey, Marc Cohen, Jyotsna Garg, et al.
Pageof 63